Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.

Autor:	Posner A; Department of Clinical Pathology and Centre for Cancer Research, The University of Melbourne, Melbourne, Victoria, Australia., Sivakumaran T; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia., Pattison A; Department of Clinical Pathology and Centre for Cancer Research, The University of Melbourne, Melbourne, Victoria, Australia., Etemadmoghadam D; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Thio N; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Wood C; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Fisher K; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Webb S; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., DeFazio A; Department of Gynaecological Oncology, and Westmead Institute for Medical Research, Westmead Hospital, Westmead, New South Wales, Australia.; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia., Wilcken N; Department of Medical Oncology, Westmead Hospital The Crown Princess Mary Cancer Centre, Sydney, New South Wales, Australia., Gao B; Department of Medical Oncology, Westmead Hospital The Crown Princess Mary Cancer Centre, Sydney, New South Wales, Australia., Karapetis CS; Department of Medical Oncology and Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia., Singh M; Department of Medical Oncology, Barwon Health Cancer Services, Geelong, Victoria, Australia., Collins IM; Department of Medical Oncology and SouthWest HealthCare, Deakin University - Warrnambool Campus, Warrnambool, Victoria, Australia., Richardson G; Medical Oncology, Cabrini Health, Malvern, Victoria, Australia., Steer C; Border Medical Oncology, Albury Wodonga Regional Cancer Centre, Albury, Victoria, Australia., Warren M; Medical Oncology, Bendigo Health, Bendigo, Victoria, Australia., Karanth N; Division of Medicine, Top End Health and Hospital Services, Alan Walker Cancer Centre, Darwin, Northern Territory, Australia., Fellowes A; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Fox SB; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Hicks RJ; St Vincent's Hospital Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia., Schofield P; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.; Behavioural Sciences Unit, Health Services Research and Implementation Sciences, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Bowtell D; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Prall OWJ; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Tothill RW; Department of Clinical Pathology and Centre for Cancer Research, The University of Melbourne, Melbourne, Victoria, Australia rtothill@unimelb.edu.au Linda.Mileshkin@petermac.org.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia., Mileshkin L; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia rtothill@unimelb.edu.au Linda.Mileshkin@petermac.org.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Jazyk:	angličtina
Zdroj:	Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Jan; Vol. 11 (1).
DOI:	10.1136/jitc-2022-005809
Abstrakt:	Background: Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited treatment options and poor survival outcomes. Immune checkpoint inhibitors (ICIs) can be efficacious in some patients with CUP, but the optimal predictive biomarkers are unknown. We therefore assessed immune and genomic biomarkers as well as predicted TOO in patients with CUP, including a subset treated with ICIs. Methods: Patients with CUP were subject to gene-expression profiling (GEP) and DNA panel sequencing. Immune and stromal-related gene expression was explored by NanoString, including genes associated with immunotherapy response (IR) in other solid malignancies. ICI responsive cancer types were assigned based on Food and Drug Administration-approved indications, and either detection of a latent primary tumor or the TOO was suspected based on genomics informed pathology review. Tumor mutation burden (TMB) and gene mutations were also assessed. Results: A total of 219 patients with CUP were included, 215 assessed for TOO in a previous study, with the majority (163) receiving both RNA and DNA tests. Of GEP profiled cases, 33% (59/175) had a high IR gene-expression score. Of the DNA sequenced cases, 16% (32/203) had high TMB (>10 mutations/Mb), including two with mismatch repair deficiency. Low correlation was observed between TMB and an IR score (R=0.26, p<0.001). Among 110 CUPs with a latent primary or suspected TOO, 47% (52/110) belonged to ICI-responsive cancer types. More than half of the CUPs had at least one feature that may predict ICI response (high IR score, high TMB, ICI-responsive cancer type). Among patients with CUP treated with ICIs, 8/28 (29%) responded (2 complete responses and 6 partial responses). Among non-responders, 9 had stable and 11 had progressive disease. All responders had a high IR score (7/8) and/or high TMB (3/8), while most (5/8) belonged to ICI-responsive cancer types. These features were detected at a lower frequency in non-responders and mostly in patients with stable disease. Conclusions: A significant fraction of CUP tumors had genomic features previously associated with ICI response. High IR score was the most sensitive predictive feature of ICI response, warranting evaluation in a larger patient series. Competing Interests: Competing interests: All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: RJH is a shareholder in Telix Pharmaceuticals and a Founder and Director of PreMIT. CSK is on the advisory board of AstraZeneca, BMS and Roche. CS is on the advisory board of MSD, Sanofi, Janssen, and GSK. ADeF has received grant funding from AstraZeneca, unrelated to this study; no other relationships or activities that could appear to have influenced the submitted work. (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu